

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Could the perioperative use of opioids influence cancer outcomes after surgery? A scoping review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054520
Article Type:	Protocol
Date Submitted by the Author:	14-Jun-2021
Complete List of Authors:	Cascella, Marco; Istituto Nazionale Tumori IRCCS Cuomo, Arturo; Istituto Nazionale Tumori IRCCS Bifulco, Francesca; Istituto Nazionale Tumori IRCCS Aprea, Marika; Division of Anesthesia Forte, Cira Antonietta; Istituto Nazionale Tumori IRCCS Carbone, Francesca; Università di Napoli Federico II, Dipartimento di Sanità Pubblica Perri, F; INT IRCCS G Pascale, Naples, Department of Head/Neck and Sarcoma Oncology Fiore , Marco; Università degli Studi della Campania Luigi Vanvitelli,
Keywords:	Anaesthesia in oncology < ANAESTHETICS, Adult oncology < ONCOLOGY, Pain management < ANAESTHETICS

SCHOLARONE™
Manuscripts

Could the perioperative use of opioids influence cancer outcomes after surgery? A scoping review protocol

Marco Cascella Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS. Fondazione G. Pascale. Mail: m.cascella@istitutotumori.na.it

Arturo Cuomo Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS. Fondazione G. Pascale. Mail: a.cuomo@istitutotumori.na.it

Francesca Bifulco Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS. Fondazione G. Pascale. Mail: f.bifulco@istitutotumori.na.it

Francesco Perri Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS. Fondazione G. Pascale. Mail: f.perri@istitutotumori.na.it

Francesca Carbone Dipartimento di Sanità Pubblica, Università di Napoli Federico II. Mail: francesca.carbone@unina.it

Marika Aprea Division of Anesthesia, Istituto Tumori Regina Elena, Roma, Italy. Mail: marika.aprea@gmail.com

Cira Antonietta Forte Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS. Fondazione G. Pascale. Mail: c.forte@istitutotumori.na.it

Marco Fiore Department of Women, Child and General and Specialized Surgery, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy. Mail: marco.fiore@hotmail.it

Corresponding author

Marco Cascella Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS. Fondazione G. Pascale. Via Mariano Semmola. 80131, Napoli, Italy
Mail: m.cascella@istitutotumori.na.it
Phone: +39 0815903221
Fax: +39 0815903779

ORCID: 0000-0002-5236-3132

ABSTRACT

Background

Opioids are commonly used for the treatment of pain, and during and after general anesthesia. Since preclinical studies underlined the potential immunosuppressive activity of these drugs, it was postulated that the perioperative administration of opioids could influence cancer outcomes after surgery. Nevertheless, clinical data have been extrapolated mainly from retrospective analyses. The precise link between perioperative opioids use and cancer recurrence/metastasis or cancer-related mortality/morbidity remains unresolved.

Methods and analysis

This scoping review is planned following the Joanna Briggs Institute recommendations. The authors will conduct a literature review through the PRISMA statement using PubMed and EMBASE databases; the Grey literature will be explored using Google Scholar, Conference Proceedings Citation Index (via Web of Science), and Open Grey. The search strategy will be limited to articles published in the English language and to human studies. The database searches are planned from the inception to August 2021. Two reviewers will independently screen titles and abstracts, followed by a full-text screening of potentially relevant articles with standardized data extraction. Any disagreement for the inclusion between the two reviewers will be discussed with a third reviewer.

Ethics and dissemination

The review aims to map the available literature, focusing on a possible association between perioperative opioids use and cancer outcomes in patients undergoing surgery. The proposed approach will be useful to identify and analyze the knowledge gap in the field and serving as a prerequisite for future research.

Scoping review registration

Open Science Framework <https://osf.io/vfhw6/> DOI 10.17605/OSF.IO/VFHW6

Keywords: Opioids, Cancer Surgery, Cancer Outcomes, Postoperative Analgesia, Opioid-free Anesthesia

Article Summary

Strengths and limitations of this study

- A strategy that limits or eliminates the use of opioids during and after surgery could induce immediate effects on perioperative outcomes and a potential improvement of the oncological course.
- The analysis of the results must be interpreted considering that clinical trials of the perioperative opioid-induced effects on cancer are difficult to conduct due to a combination of anesthetic and no-anesthetic agents used.
- Because of the inclusion of publications written only in the English language, the search may exclude relevant articles in other languages.
- The broad search strategy might be associated with less accuracy on the aim of the review that may result in a large number of redundant references.

Background

Opioids are a class of drugs used for the treatment of pain, and to control analgesia during and after general anesthesia. From the end of the last century, several preclinical investigations were conducted on the potential immunosuppressive activity of opioids. The impact of these agents on both the innate and adaptive immune systems was emphasized.¹ Since many factors such as the type of opioid, the dose, the timing of administration, and the animal strain used, can influence the data, these findings are not conclusive. Later, in individuals with a history of opioid abuse, the effects of morphine on the immune system were studied.² Furthermore, an association between opioid use and higher risk of infections was found in patients treated for chronic non cancer pain.³ Nevertheless, to date, the evidence is not strong enough to establish a clear link between chronic opioid use and immunosuppression.⁴ Moreover, doubts raised about impact of opioid administration given for a limited period such as the surgical phase and a short postoperative period on immunity. Interestingly, intraoperative opioids can increase expression of opioid receptor in cancer tissues without influencing the expression of immune cell markers.⁵

In the context of the intraoperative phase, anesthesia strategies focused on low-dose opioid use or opioid-avoiding paths (i.e., opioid-free anesthesia, OFA) are rapidly growing, even in cancer surgery.⁶ The motivations underlying this phenomenon are multiple. Synthetic short-acting opioids, for instance, can increase postoperative pain through opioid-induced hyperalgesia mechanisms. Again, the use of opioids during and after surgery can lead to a delay in patient mobilization, a slowing of intestinal peristalsis, and an increase in postoperative nausea and vomiting (PONV). Finally, the concern of a potential postoperative opioids over prescriptions is another serious reason that tends to direct the anesthetic choices towards an opioid-free approach. The OFA strategy is based on the concept of multimodal anesthesia which combines different drugs and/or techniques.⁷ In the whole perioperative setting, regional anesthesia techniques are pivotal components of this multimodal pain management. These methods could influence the long-term outcome of cancer surgery, mostly by attenuating the immunosuppression effects due to surgery.⁸

In the setting of cancer patients, in addition to the effects on the early postoperative, a debate is underway on possible opioid-induced long-term sequelae. To date, most of the scientific evidence in favor of this thesis comes from preclinical studies while clinical data have been extrapolated mainly from retrospective analyses.⁹ For instance, a retrospective study on patients who underwent prostatectomy for cancer showed that patients treated through epidural analgesia had a significant reduction in cancer recurrence compared to those managed with opioids.¹⁰ On the other hand, a recent controlled investigation demonstrated that regional anesthesia-analgesia approaches did not reduce breast cancer recurrence compared with standard opioid-based anesthesia.¹¹ Recently, a systematic review that included 13 studies on perioperative opioids and colorectal cancer recurrence found no conclusive results. Furthermore, the authors decided to not perform the meta-analysis because of the low quality of the primary studies.¹² Thus, the precise link between perioperative opioids and cancer recurrence or metastasis, as well as survival remains unresolved.

Implications

This scoping review may clarify doubts on an extremely important topic. The task is to understand, in a cancer patient, if an approach that limits or eliminates the use of opioids during and after surgery has immediate effects such as the reduction of PONV, rapid mobilization, and reduced inhibition of peristalsis. A potential improvement of the oncological outcomes is also investigated.

Methods and analysis

Protocol design

The protocol was registered prospectively with the Open Science Framework in June 2021.¹³ It has been planned, according the JBI Scoping Review Methodology Group,¹⁴ following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews (PRISMA-ScR).¹⁵

Patient and public involvement

Patients and public were not involved in the preparation of this protocol.

Research questions

This review is planned to answer the following research question:

Could the perioperative use of opioids influence cancer outcomes after surgery?

The research sub-questions include:

1. Is it possible to find possible differences according to the type of opioid used?
2. Is there a correlation between chronic opioid use and variation in outcomes in cancer patients?
3. Are there any differences related to the type of multimodal analgesia applied?

Eligibility criteria

Primary studies of any design will be included. No restrictions on publication year will be adopted. We will exclude unpublished works as a full-text, abstract, conference meetings, studies published in not peer-review journals, uncontrolled studies as case series or case reports, reviews, and studies published not in English.

Manuscripts will be excluded if they do not match the assumed framework of the study, centered on opioids administration and cancer recurrence or metastasis after surgery (Table 1).

	Inclusion	Exclusion
Study design	Primary studies of any design	Systematic reviews, meta-analysis, narrative reviews, letter to editor, case reports, case series, animal studies, in vitro investigations, studies on human volunteers
Population	Patients who underwent surgery for cancer disease	n/a
Intervention/exposure	Administration of opioids for treatment of pain/anesthesia	n/a
Comparator	Methods of opioid-free anesthesia	No opioids should be administered in the whole perioperative
Outcomes	Disease-free survival and/or overall survival	Those other than the chosen outcomes
Language	English	Those other than in English
Publication status	Published in peer review journals, full-length articles	Published in not peer-review journals, unpublished works as a full-text, abstract, conference meetings
Others	All study dates, length of follow-up, setting	n/a

Search Strategy

The search strategy will be defined following the PICO strategy. The Population will be patients who underwent surgery for cancer disease, and the Intervention will be the administration of opioids alone or in combination with other drugs used for both treatment of pain perioperatively and anesthesia management. The Comparator will be any method of opioid-free anesthesia regional anesthesia-analgesia approaches for the perioperative management of pain. The Outcomes will be the time of disease-free survival, and the overall survival. The search strings follow the evidence-based guideline for Peer Review of Electronic Search Strategies (PRESS) for systematic reviews, health technology assessments, and other evidence syntheses developed by McGowan and colleagues.¹⁶ A proposed search string for Medline, via Ovid, is detailed in Table 2; the search strategies for the other databases will be comparable in structure with similar search terms and synonyms.

A consequent search using keywords and index terms will be performed using several computer-assisted databases, including PubMed, EMBASE, and for the grey literature: Google Scholar, Conference Proceedings Citation Index (via Web of Science) and Open Grey. The search strategy will be limited to articles published in English language and to human studies.

Searches		Results
1.	cancer.mp.	1870659
2.	oncolog*.mp.	187417
3.	1 or 2	1949974
4.	exp managment/ or exp treatment/	4747134
5.	pain.mp.	762846
6.	opioid.mp.	118491
7.	4 and 5 and 6	23127
8.	monitor*.mp.	1031816
9.	7 and 8	1436
10.	3 and 9	242

Study selection

Articles will be selected by the authors by evaluating titles and abstracts to identify potentially eligible studies; subsequently, the full text of eligible studies will be reviewed by the authors to exclude irrelevant studies or methodologies that are not usable for future analysis.

Data charting

The reviewers will record key information from included articles in a Microsoft Excel data extraction form. Two reviewers (FB and CAF) will independently extract data to minimize errors. Each study will be extracted with the following information: title, year of publication, first author, the country where the study was conducted, type of study, lying cancer disease for which the surgery was required, anesthesia method, type and dose of the opioid(s), type of multimodal analgesia (regional techniques, drugs), and outcomes including type of recurrence or metastasis, time elapsed since surgery, and overall survival.

Data synthesis

The number of studies identified and selected at each stage of the scoping review and the reasons for exclusion will be presented in the PRISMA flow diagram. Results will be recapitulated in a table (Table 3) and exhaustively discussed in narrative way to address the research questions.

Results will be assembled conceptually in terms of general study details, study characteristics, participants, interventions/exposures/comparators, instruments used in goal-setting, outcomes, and results. This review will illustrate summaries of these categories, including quantitative measurements of associations (mean differences for scores by validated questionnaires, risk ratios, or odds ratios for dichotomous outcomes), if applicable. Additional groups may be identified during the extraction of results. Authors of papers will be contacted to request missing or additional data for clarification, where required. We will report the results of critical appraisal in narrative form and in one or more tables.

Risk of bias

As this is a scoping review, there will be no risk of bias assessment. This is consistent with relevant guidance.¹⁷

General study details	Study ID number, lead author, title, journal, year of publication, type of publication, information source
Study characteristics	Study design, study duration, pilot/feasibility study (y/n), number of study arms, covariates (definition and measurement methods)
Participants	<ol style="list-style-type: none"> 1. Total number, setting, inclusion and exclusion criteria 2. Participant characteristics at baseline: for each study, average age (years, mean and standard deviation [SD]), sex (%), country, diagnosis (cancer type, stage), treatment(s), comorbidities
Interventions/exposures and comparators	<ol style="list-style-type: none"> 1. Total number of intervention/exposure [opioid(s) type, doses, opioid administration and surgery (pre-, intra-, postoperatively), time of treatment], and comparison [No opioid use] groups and number of participants in each group 2. For each intervention/exposure and comparison group: intervention/exposure/comparison, duration of intervention/exposure, who and how assessed, and results of assessment
Outcomes	Type of recurrence or metastasis; time elapsed since surgery; overall survival
Results	For each quantitative outcome: sample size, number of missing participants, reasons for loss to follow up, summary data for each group (2 × 2 table for dichotomous data, means and SDs for continuous data), estimate of effect for the difference between groups (or change in baseline and final scores for single-arm studies), confidence intervals, and <i>p</i> value

Strengths and limitations of this study

This scoping review aims to describe the link between perioperative opioids and cancer recurrence or metastasis. The subject is particularly complex. The main issue is to establish what is the weight of the intervention in the determinism of outcomes. The outcomes considered, indeed, may be dependent on multiple factors such as type of opioid and dose. For both variables, literature data are conflicting.¹⁸ Moreover, it will be important to accurately extract data on the disease (stage, grading). For example, in prostate cancer, a Gleason 4 + 3 = 7 will have a higher probability of developing recurrence or metastasis than a Gleason 3 + 4 = 7. The effect of opioids may vary depending on the stage of the tumor. To this regard, Cata et al.¹⁹ found that intraoperative opioid was associated with reduced overall survival for patients with early-stage non-small cell lung cancer compared to those affected by more advanced disease.

1
2
3 Another important challenge regards the potential immunosuppressive effects among patients
4 receiving preoperatively opioids for the management of chronic cancer pain. Our goal is that the
5 proposed approach will allow to identify and analyze the knowledge gap in the field and, in turn,
6 will serve as a prerequisite for future research including systematic review and clinical studies.

7 Although we will follow an accurate method for this scoping review, several limitations are
8 anticipated. Because of the inclusion of publications written only in the English language, the
9 search may exclude relevant articles in other languages. Furthermore, our broad search strategy
10 might be associated with less accuracy on the aim of the review that may result in a large number of
11 redundant references. Third, the analysis of the results must be interpreted considering that clinical
12 trials of the perioperative opioid-induced effects on cancer are difficult to conduct, as during the
13 perioperative care patients require a combination of anesthetic and no-anesthetic agents. These
14 limitations could lead to serious inconsistency and/or risk of bias, downgrading the outcomes.
15
16
17

18 **Data statement**

19 The datasets generated during the current study and the analytical methods (including preprocessing
20 and eventually the analysis code) will be available from the corresponding author on reasonable
21 request.
22
23

24 **Ethics and dissemination**

25 **Ethics Approval and Consent to participate**

26 This paper does not require ethics approval.

27 **Consent for publication**

28 Not applicable.

29 **Competing interests**

30 The authors declare that they have no competing interests.

31 **Funding**

32 This research received no specific grant from any funding agency in the public, commercial or not-
33 for-profit sectors.
34
35
36
37
38

39 **Data dissemination**

40 The results of this scoping review will be disseminated on the authors' web sites. Additional
41 dissemination will occur through presentations at conferences, such as courses and science
42 education conferences, regionally and nationally, and through articles published in peer-reviewed
43 journals. Workshops with health care professionals involved in the management of cancer pain,
44 oncology, and cancer surgery will be planned.
45
46

47 **Author contributions**

48 This study was mainly written by MC, and MF. FB, and CAF collected the data. FC and CAF
49 supervised the writing of the paper. AC, MA, and FP critically revised the paper. All authors gave
50 final approval of the version to be published and agreed to be accountable for all aspects of the
51 work.
52

53 **Acknowledgements**

54 We would like to thank Maria Cristina Romano for copyediting.
55
56

57 **Word count**

58 3196
59

60 **References**

1. Bhaskaran M, Reddy K, Sharma S, et al. Morphine-induced degradation of the host defense barrier: role of macrophage injury. *J Infect Dis* 2001;184(12):1524-31. doi: 10.1086/324667
2. Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. *J Neuroimmune Pharmacol* 2011;6(4):442-65. doi: 10.1007/s11481-011-9292-5
3. Wiese AD, Griffin MR, Stein CM, et al. Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study. *Arthritis Rheumatol* 2016;68(2):323-31. doi: 10.1002/art.39462
4. Plein LM, Rittner HL. Opioids and the immune system - friend or foe. *Br J Pharmacol* 2018;175(14):2717-25. doi: 10.1111/bph.
5. Levins KJ, Prendeville S, Conlon S, et al. The effect of anesthetic technique on micro-opioid receptor expression and immune cell infiltration in breast cancer. *J Anesth* 2018;32(6):792-96. doi: 10.1007/s00540-018-2554-0
6. Malo-Manso A, Raigon-Ponferrada A, Diaz-Crespo J, et al. Opioid Free Anaesthesia and Cancer. *Curr Pharm Des* 2019;25(28):3011-19. doi: 10.2174/1381612825666190705183754
7. Veyckemans F. Opioid-free anaesthesia: Still a debate? *Eur J Anaesthesiol* 2019;36(4):245-46. doi: 10.1097/EJA.0000000000000964
8. Kaye AD, Patel N, Bueno FR, et al. Effect of opiates, anesthetic techniques, and other perioperative factors on surgical cancer patients. *Ochsner J* 2014;14(2):216-28.
9. Kim R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. *J Transl Med* 2018;16(1):8. doi: 10.1186/s12967-018-1389-7
10. Biki B, Mascha E, Moriarty DC, et al. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. *Anesthesiology* 2008;109(2):180-7. doi: 10.1097/ALN.0b013e31817f5b73
11. Sessler DI, Pei L, Huang Y, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. *Lancet* 2019;394(10211):1807-15. doi: 10.1016/s0140-6736(19)32313-x
12. Diaz-Cambronero O, Mazzinari G, Cata JP. Perioperative opioids and colorectal cancer recurrence: a systematic review of the literature. *Pain Manag* 2018;8(5):353-61. doi: 10.2217/pmt-2018-0029
13. Cascella M. Templated from Could the perioperative use of opioids influence cancer outcome after surgery? A scoping review protocol. 2021 doi: 10.17605/OSF.IO/VFHW6
14. Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Implement* 2021;19(1):3-10. doi: 10.1097/XEB.0000000000000277
15. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med* 2018;169(7):467-73. doi: 10.7326/M18-0850
16. McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol* 2016;75:40-6. doi: 10.1016/j.jclinepi.2016.01.021
17. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International Journal of Social Research Methodology* 2005;8(1):19-32. doi: 10.1080/1364557032000119616
18. Oh TK, Jeon JH, Lee JM, et al. Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery. *PLoS One* 2017;12(7):e0181672. doi: 10.1371/journal.pone.0181672

19. Cata JP, Keerty V, Keerty D, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. *Cancer Med* 2014;3(4):900-8. doi: 10.1002/cam4.236

For peer review only

BMJ Open

Could the perioperative use of opioids influence cancer outcomes after surgery? A scoping review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054520.R1
Article Type:	Protocol
Date Submitted by the Author:	06-Jan-2022
Complete List of Authors:	Cascella, Marco; Istituto Nazionale Tumori IRCCS Cuomo, Arturo; Istituto Nazionale Tumori IRCCS Bifulco, Francesca; Istituto Nazionale Tumori IRCCS Perri, F; INT IRCCS G Pascale, Naples, Department of Head/Neck and Sarcoma Oncology Carbone, Francesca; Università di Napoli Federico II, Dipartimento di Sanità Pubblica Aprea, Marika; Division of Anesthesia Forte, Cira Antonietta; Istituto Nazionale Tumori IRCCS Fiore, Marco; Università degli Studi della Campania Luigi Vanvitelli,
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Patient-centred medicine, Research methods, Surgery, Anaesthesia, Addiction
Keywords:	Anaesthesia in oncology < ANAESTHETICS, Adult oncology < ONCOLOGY, Pain management < ANAESTHETICS, Adult anaesthesia < ANAESTHETICS

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Could the perioperative use of opioids influence cancer outcomes after surgery?**

2 **A scoping review protocol**

3
4
5
6
7 4 *Marco Cascella* Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS.
8 5 Fondazione G. Pascale. Mail: m.cascella@istitutotumori.na.it

9 6
10 7
11 7 *Arturo Cuomo* Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS.
12 8 Fondazione G. Pascale. Mail: a.cuomo@istitutotumori.na.it

13 9
14 10
15 11 *Francesca Bifulco* Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS.
16 12 Fondazione G. Pascale. Mail: f.bifulco@istitutotumori.na.it

17 13
18 13 *Francesco Perri* Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS.
19 14 Fondazione G. Pascale. Mail: f.perri@istitutotumori.na.it

20 15
21 16 *Francesca Carbone* Dipartimento di Sanità Pubblica, Università di Napoli Federico II. Mail:
22 17 francesca.carbone@unina.it

23 18
24 19 *Marika Aprea* Division of Anesthesia, Istituto Tumori Regina Elena, Roma, Italy. Mail:
25 20 marika.aprea@gmail.com

26 21
27 22
28 22 *Cira Antonietta Forte* Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS.
29 23 Fondazione G. Pascale. Mail: c.forte@istitutotumori.na.it

30 24
31 25 *Marco Fiore* Department of Women, Child and General and Specialized Surgery, Università degli
32 26 Studi della Campania Luigi Vanvitelli, Napoli, Italy. Mail: marco.fiore@hotmail.it

34 27 **Corresponding author**

35 28
36 29
37 30 *Marco Cascella* Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS.
38 31 Fondazione G. Pascale. Via Mariano Semmola. 80131, Napoli, Italy

39 32 Mail: m.cascella@istitutotumori.na.it

40 33 Phone: +39 0815903221

41 34 Fax: +39 0815903779

42 35
43 36
44 36 ORCID: 0000-0002-5236-3132

ABSTRACT

Background

During and after general anesthesia, opioids are commonly used for pain treatment. Since preclinical studies underlined the potential immunosuppressive activity of these drugs, it was postulated that their perioperative administration could influence cancer outcomes after surgery. Nevertheless, clinical data have been extrapolated mainly from retrospective analyses. Consequently, the precise link between perioperative opioid use and cancer recurrence/metastasis or cancer-related mortality/morbidity is still an unsolved issue.

Methods and analysis

This scoping review is planned to follow the Joanna Briggs Institute recommendations. The authors will conduct a literature review through the PRISMA statement using PubMed and EMBASE databases; the Grey literature will be explored using Google Scholar and Conference Proceedings Citation Index (via Web of Science). The search strategy will be limited to articles published in the English language and to human studies. The database searches are planned from the inception to January 2022. Two reviewers will independently screen titles and abstracts, followed by a full-text screening of potentially relevant articles with standardized data extraction. Any disagreement for the inclusion between the two reviewers will be discussed with a third reviewer.

Ethics and dissemination

The review aims to map the available literature, focusing on a possible association between perioperative opioid use and cancer outcomes in patients undergoing surgery. The proposed approach will be useful to identify and analyze the knowledge gap in the field and serve as a prerequisite for future research.

Scoping review registration

Open Science Framework <https://osf.io/vfhw6/> DOI 10.17605/OSF.IO/VFHW6

Keywords: Opioids, Cancer Surgery, Cancer Outcomes, Postoperative Analgesia, Opioid-free Anesthesia

Article Summary

Strengths and limitations of this study

- A strategy that limits or eliminates the use of opioids during and after surgery could induce immediate effects on perioperative outcomes and a potential improvement of the oncological course.
- The analysis of the results must be interpreted considering that clinical trials of the perioperative opioid-induced effects on cancer are difficult to conduct due to a combination of anesthetic and no-anesthetic agents used.
- Because of the inclusion of publications written only in the English language, the search may exclude relevant articles in other languages.
- The broad search strategy might be associated with less accuracy on the aim of the review that may result in many redundant references.

83 **Background**

84
85 Opioids are a class of drugs used to control analgesia during and after general anesthesia. From the
86 end of the last century, several preclinical investigations were conducted on their potential
87 immunosuppressive activity. The impact of these agents on both the innate and adaptive immune
88 systems was underlined.¹ Since many factors such as the type of opioid, the dose, the timing of
89 administration, and the animal strain used, can influence the data, these findings are not conclusive.
90 Later, in individuals with a history of opioid abuse, the effects of morphine on the immune system
91 were studied.² Furthermore, an association between opioid use and a higher risk of infections was
92 found in patients treated for chronic non-cancer pain.³ Nevertheless, to date, the evidence is not strong
93 enough to establish a clear link between chronic opioid use and immunosuppression.⁴
94 The role of opioids in cancer development, progression, and metastasis is an open issue.⁵ Chronic or
95 short-term use of these drugs could have different effects on these phenomena, and it could be
96 assumed that prolonged use plays a more important role in tumor progression and development.
97 Nevertheless, doubts were also raised about the impact of opioid administration given for a limited
98 period, such as the surgical phase and the immediate postoperative period, on immunity. Thus, in the
99 setting of cancer patients undergoing surgery, there is a debate about possible opioid-induced long-
100 term oncological sequelae. To date, however, most of the scientific evidence in favor of this thesis
101 comes from preclinical studies⁶ while clinical data have been mainly extrapolated from retrospective
102 analyses.^{7,8} For example, since preclinical investigations demonstrated that the mu-opioid receptor
103 (MOR) is often expressed in cancer tissues, patients requiring increased intraoperative opioid doses
104 could show worse outcomes, especially if they express high MOR levels.⁹ Interestingly, the
105 expression of MORs in some tumors (e.g., pancreatic ductal adenocarcinoma) and not in others could
106 explain how, in some studies, the higher intraoperative opioid administration could be associated with
107 better oncological outcomes.⁷ Notably, intraoperative opioids can increase the expression of opioid
108 receptors in cancer tissues without influencing the expression of immune cell markers.¹⁰
109 About clinical data, a retrospective study on patients who underwent prostatectomy for cancer showed
110 that the use of epidural analgesia involved a significant reduction in cancer recurrence compared to
111 those managed with systemic opioids.¹¹ On the other hand, a recent controlled investigation
112 demonstrated that regional anesthesia-analgesia approaches did not reduce breast cancer recurrence
113 compared with standard opioid-based anesthesia.¹² Moreover, a retrospective study found that higher
114 intraoperative opioid doses were significantly associated with better recurrence-free survival
115 ($p=0.028$), but not with increased overall survival.⁶ Recently, a systematic review that included 13
116 studies on perioperative opioids and colorectal cancer recurrence found no conclusive results.
117 Furthermore, the authors decided to not perform the meta-analysis because of the low quality of the
118 primary studies.¹³ Indeed, conducting studies on the subject is extremely complex. The analysis of
119 the results must be interpreted considering the combination of anesthetic and no-anesthetic agents
120 used. In brief, the potential impact of perioperative opioid administration and oncological outcomes
121 has several confounders. Perioperative interventions such as fluid therapy and anesthetic techniques
122 must be carefully addressed.^{14,15}
123 On these premises, the precise link between perioperative opioids and cancer recurrence or metastasis,
124 as well as survival is still an unsolved problem.^{16,17}

126 **Implications**

127 This scoping review may clarify doubts on an extremely important topic. The task is to understand,
128 in a cancer patient, if an approach that limits or eliminates the use of opioids during and after surgery
129 could influence cancer outcomes.

131 **Methods and analysis**

133 **Protocol design**

The protocol was registered prospectively with the Open Science Framework in June 2021.¹⁸ It has been planned, according to the JBI Scoping Review Methodology Group,¹⁹ following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews (PRISMA-ScR).²⁰

Patient and public involvement

Patients and public were not involved in the preparation of this protocol.

Research questions

This review is planned to answer the following research question:

Could the perioperative use of opioids influence cancer outcomes after surgery?

The research sub-questions include:

1. Is it possible to find possible differences according to the type of opioid used?
2. Is there a correlation between chronic opioid use and variation in outcomes in cancer patients?
3. Are there any differences related to the type of multimodal analgesia applied?

Eligibility criteria

Primary studies of any design will be included. No restrictions on publication year will be adopted. We will exclude unpublished works as a full-text, abstract, conference meetings, studies published in not peer-review journals, uncontrolled studies as case series or case reports, reviews, and studies published not in English.

Manuscripts will be excluded if they do not match the assumed framework of the study, centered on opioids administration and cancer recurrence or metastasis after surgery (Table 1).

Table 1. Eligibility criteria		
	Inclusion	Exclusion
Study design	Primary studies of any design	Systematic reviews, meta-analysis, narrative reviews, letters to the editor, case reports, case series, animal studies, in vitro investigations, studies on human volunteers
Population	Patients who underwent surgery for cancer disease	n/a
Intervention/exposure	Administration of opioids for the treatment of pain/anesthesia	n/a
Comparator	Methods of opioid-free anesthesia	No opioids should be administered in the whole perioperative
Outcomes	Disease-free survival and/or overall survival	Those other than the chosen outcomes
Language	English	Those other than in English
Publication status	Published in peer review journals, full-length articles	Published in not peer-review journals, unpublished works as a full-text, abstract, conference meetings
Others	All study dates, length of follow-up, setting	n/a

Search Strategy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The search strategy will be defined following the PICO strategy. The Population will be patients who underwent surgery for cancer disease, and the Intervention will be the administration of opioids alone or in combination with other drugs used for both treatment of pain perioperatively and anesthesia management. The Comparator will be any method of opioid-free anesthesia regional anesthesia-analgesia approaches for the perioperative management of pain. The Outcomes will be the time of disease-free survival, and the overall survival. The search strings follow the evidence-based guideline for Peer Review of Electronic Search Strategies (PRESS) for systematic reviews, health technology assessments, and other evidence syntheses developed by McGowan and colleagues.²¹ A proposed search string for Medline, via Ovid, is detailed in Table 2; the search strategies for the other databases will be comparable in structure with similar search terms and synonyms.

A consequent search using keywords and index terms will be performed using several computer-assisted databases, including PubMed, EMBASE, and for the grey literature: Google Scholar and Conference Proceedings Citation Index (via Web of Science). The search strategy will be limited to articles published in the English language and to human studies (in supplementary file the full search strategies utilized for all databases).

Table 2. Scoping Review Search Strategy Ovid Medline Search Strategy (January 2, 2022)

Searches		Results
1.	cancer.mp.	1953928
2.	oncolog*.mp.	198380
3.	1 or 2	2037054
4.	surgery.mp.	2848733
5.	3 and 4	317280
6.	opioid.mp.	123308
7.	5 and 6	1111
8.	monitor*.mp.	1073758
9.	Follow-Up Studies/	678247
10.	8 or 9	1724632
11.	7 and 10	101

Study selection

Articles will be selected by the authors by evaluating titles and abstracts to identify potentially eligible studies; subsequently, the full text of eligible studies will be reviewed by the authors to exclude irrelevant studies or methodologies that are not usable for future analysis.

Data charting

The reviewers will record key information from included articles in a Microsoft Excel data extraction form. Two reviewers (FB and CAF) will independently extract data to minimize errors. Each study will be extracted with the following information: title, year of publication, first author, the country where the study was conducted, type of study, lying cancer disease for which, the surgery was required, anesthesia method, type, and dose of the opioid(s), type of multimodal analgesia (regional techniques, drugs), and outcomes including the type of recurrence or metastasis, the time elapsed since surgery, and overall survival.

Data synthesis

The number of studies identified and selected at each stage of the scoping review and the reasons for exclusion will be presented in the PRISMA flow diagram. Results will be recapitulated in a table

(Table 3) and exhaustively discussed in a narrative way to address the research questions. Results will be assembled conceptually in terms of general study details, study characteristics, participants, interventions/exposures/comparators, instruments used in goal setting, outcomes, potential confounders, and results. This review will illustrate summaries of these categories, including quantitative measurements of associations (mean differences for scores by validated questionnaires, risk ratios, or odds ratios for dichotomous outcomes), if applicable. Additional groups may be identified during the extraction of results. Authors of papers will be contacted to request missing or additional data for clarification, where required. We will report the results of critical appraisal in narrative form and in one or more tables.

Risk of bias

As this is a scoping review, there will be no risk of bias assessment. This is consistent with relevant guidance.²²

Table 3. Planned variables to be extracted in the scoping review

General study details	Study ID number, lead author, title, journal, year of publication, type of publication, information source
Study characteristics	Study design, study duration, pilot/feasibility study (y/n), number of study arms, covariates (definition and measurement methods)
Participants	<ol style="list-style-type: none"> 1. Total number, setting, inclusion and exclusion criteria 2. Participant characteristics at baseline: for each study, average age (years, mean and standard deviation [SD]), sex (%), country, diagnosis (cancer type, stage), treatment(s), comorbidities
Interventions/exposures and comparators	<ol style="list-style-type: none"> 1. Total number of intervention/exposure [opioid(s) type, doses, opioid administration and surgery (pre-, intra-, postoperatively), time of treatment], and comparison [No opioid use] groups and number of participants in each group 2. For each intervention/exposure and comparison group: intervention/exposure/comparison, duration of intervention/exposure, who and how assessed, and results of the assessment
Outcomes	Type of recurrence or metastasis; time elapsed since surgery; overall survival
Potential confounders	For example, fluid therapy, and anesthetic techniques
Results	For each quantitative outcome: sample size, number of missing participants, reasons for loss to follow up, summary data for each group (a 2×2 table for dichotomous data, means and SDs for continuous data), the estimate of effect for the difference between groups (or change in baseline and final scores for single-arm studies), confidence intervals, and <i>p</i> -value

Strengths and limitations of this study

This scoping review aims to describe the link between perioperative opioids and cancer recurrence or metastasis. The subject is particularly complex. The main issue is to establish what is the weight of the intervention in the determinism of outcomes. The outcomes considered, indeed, may be dependent on multiple factors such as type of opioid and dose. For both variables, literature data are conflicting.²³ Moreover, it will be important to accurately extract data on the disease (stage, grading). For example, in prostate cancer, a Gleason 4 + 3 = 7 will have a higher probability of developing recurrence or metastasis than a Gleason 3 + 4 = 7. The effect of opioids may vary depending on the stage of the tumor. In this regard, in a retrospective analysis, Cata et al.²⁴ found that intraoperative

1
2

3 222 opioid was associated with reduced overall survival for patients with early-stage non-small cell lung
4 223 cancer compared to those affected by the more advanced disease.

5 224 Another important challenge regards the potential immunosuppressive effects among patients
6 225 receiving, preoperatively, opioids for the management of chronic cancer pain. Our goal is that the
7 226 proposed approach will allow us to identify and analyze the knowledge gap in the field and, in turn,
8 227 will serve as a prerequisite for future research including systematic review and clinical studies.

9 228 Although we will follow an accurate method for this scoping review, several limitations are
10 229 anticipated. Because of the inclusion of publications written only in the English language, the search
11 230 may exclude relevant articles in other languages. Furthermore, our broad search strategy might be
12 231 associated with less accuracy on the aim of the review that may result in many redundant references.
13 232 Third, the analysis of the results must be interpreted considering that clinical trials of the perioperative
14 233 opioid-induced effects on cancer are difficult to conduct, as during the perioperative care patients
15 234 require a combination of anesthetic and no-anesthetic agents. These limitations could lead to serious
16 235 inconsistency and/or risk of bias, downgrading the outcomes.

17 236

21 237 **Data statement**

22 238 The datasets generated during the current study and the analytical methods (including preprocessing
23 239 and eventually the analysis code) will be available from the corresponding author on reasonable
24 240 request.

25 241

27 242 **Ethics and dissemination**

28 243

29 244 **Ethics Approval and Consent to participate**

30 245 This paper does not require ethics approval.

32 246 **Consent for publication**

33 247 Not applicable.

34 248 **Competing interests**

35 249 The authors declare that they have no competing interests.

36 250 **Funding**

37 251 This research received no specific grant from any funding agency in the public, commercial or not-
38 252 for-profit sectors.

39 253

41 254 **Data dissemination**

42 255 The results of this scoping review will be disseminated on the authors' websites. Additional
43 256 dissemination will occur through presentations at conferences, such as courses and science education
44 257 conferences, regionally and nationally, and through articles published in peer-reviewed journals.
45 258 Workshops with health care professionals involved in the management of cancer pain, oncology, and
46 259 cancer surgery will be planned.

47 260

49 261 **Author contributions**

50 262 This study was mainly written by MC, and MF. FB, and CAF collected the data. FC and CAF
51 263 supervised the writing of the paper. AC, MA, and FP critically revised the paper. All authors gave
52 264 final approval of the version to be published and agreed to be accountable for all aspects of the work.

53 265

55 266 **Acknowledgments**

56 267 We would like to thank Ms. Maria Cristina Romano for copyediting.

57 268

58 269 **Word count**

59 270 3196

60 271

References

1. Bhaskaran M, Reddy K, Sharma S, et al. Morphine-induced degradation of the host defense barrier: role of macrophage injury. *J Infect Dis* 2001;184(12):1524-31. doi: 10.1086/324667
2. Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. *J Neuroimmune Pharmacol* 2011;6(4):442-65. doi: 10.1007/s11481-011-9292-5
3. Wiese AD, Griffin MR, Stein CM, et al. Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study. *Arthritis Rheumatol* 2016;68(2):323-31. doi: 10.1002/art.39462
4. Plein LM, Rittner HL. Opioids and the immune system - friend or foe. *Br J Pharmacol* 2018;175(14):2717-25. doi: 10.1111/bph.
5. Szczepaniak A, Fichna J, Zielińska M. Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer. *Curr Treat Options Oncol* 2020;21(1):6. doi: 10.1007/s11864-019-0699-1
6. Bimonte S, Barbieri A, Cascella M, et al. Naloxone Counteracts the Promoting Tumor Growth Effects Induced by Morphine in an Animal Model of Triple-negative Breast Cancer. *In Vivo*. 2019;33(3):821-825. doi: 10.21873/invivo.11545.
7. Montagna G, Gupta HV, Hannum M, et al. Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. *Br J Anaesth*. 2021; 126(2):367-376. doi: 10.1016/j.bja.2020.10.021
8. Kim R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. *J Transl Med* 2018;16(1):8. doi: 10.1186/s12967-018-1389-7
9. Zhang H, Qu M, Gorur A, et al. Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma. *Front Oncol*. 2021;11:686877. doi: 10.3389/fonc.2021.686877
10. Levins KJ, Prendeville S, Conlon S, et al. The effect of anesthetic technique on micro-opioid receptor expression and immune cell infiltration in breast cancer. *J Anesth* 2018;32(6):792-96. doi: 10.1007/s00540-018-2554-0
11. Biki B, Mascha E, Moriarty DC, et al. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. *Anesthesiology* 2008;109(2):180-7. doi: 10.1097/ALN.0b013e31817f5b73
12. Sessler DI, Pei L, Huang Y, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. *Lancet* 2019;394(10211):1807-15. doi: 10.1016/s0140-6736(19)32313-x
13. Diaz-Cambronero O, Mazzinari G, Cata JP. Perioperative opioids and colorectal cancer recurrence: a systematic review of the literature. *Pain Manag* 2018;8(5):353-61. doi: 10.2217/pmt-2018-0029
14. Xu ZZ, Li HJ, Li MH, et al. Epidural Anesthesia-Analgesia and Recurrence-free Survival after Lung Cancer Surgery: A Randomized Trial. *Anesthesiology*. 2021;135(3):419-432. doi: 10.1097/ALN.0000000000003873
15. Zorrilla-Vaca A, Ripolles-Melchor J, Fernandez-Valdes P, Ruiz-Escobar A. Association of Liberal Fluid Therapy for Colorectal Cancer Surgery and Long-Term Oncologic Recurrence. *Ann Surg Oncol*. 2021 Nov. doi: 10.1245/s10434-021-11046-2
16. Ramirez MF, Gorur A, Cata JP. Opioids and cancer prognosis: A summary of the clinical evidence. *Neurosci Lett*. 2021;746:135661. doi: 10.1016/j.neulet.2021.135661.
17. Kaye AD, Patel N, Bueno FR, et al. Effect of opiates, anesthetic techniques, and other perioperative factors on surgical cancer patients. *Ochsner J* 2014;14(2):216-28.
18. Cascella M. Templated from Could the perioperative use of opioids influence cancer outcome after surgery? A scoping review protocol. 2021 doi: 10.17605/OSF.IO/VFHW6

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

19. Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Implement* 2021;19(1):3-10. doi: 10.1097/XEB.0000000000000277
20. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med* 2018;169(7):467-73. doi: 10.7326/M18-0850
21. McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol* 2016;75:40-6. doi: 10.1016/j.jclinepi.2016.01.021
22. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International Journal of Social Research Methodology* 2005;8(1):19-32. doi: 10.1080/1364557032000119616
23. Oh TK, Jeon JH, Lee JM, et al. Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery. *PLoS One* 2017;12(7):e0181672. doi: 10.1371/journal.pone.0181672
24. Cata JP, Keerty V, Keerty D, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. *Cancer Med* 2014;3(4):900-8. doi: 10.1002/cam4.236

1
2
3
4 **Search strategy**
5

6
7 **PubMed**

8 (((Cancer OR oncolog*) AND surgery) AND opioid) AND (monitor* OR follow-up)
9

10
11 **Embase**

12 ('cancer'/exp OR cancer OR oncolog*) AND ('surgery'/exp OR surgery) AND 'opioid'/exp AND
13 (monitor* OR 'follow up'/exp OR 'follow up')
14

15 **Google Scholar via Publish or Perish (macOS GUI Edition) in Keywords:**

16 (((Cancer OR oncolog*) AND surgery) AND opioid) AND (monitor* OR follow-up)
17
18

19 **Conference Proceedings Citation Index- Science (CPCI-S) --1990-present via Web of Science:**

20 ((Cancer OR oncolog*) AND surgery) AND opioid
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	Page 1 Lines: 1-2
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	Page 2 Lines: 37-61
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	Page 3 Lines 83-124
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	Pag 4 Lines:141-147
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	Pag 4 Line: 134
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	Pag 4 Lines: 150-159
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	Page 5 Lines: 170-174
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Page 5 Lines 175-177
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	Page 5 Lines 178-181
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	Page 5 Lines: 183-190
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	Pag 6 Lines: 199-204
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	Page 6 Lines: 206-207
Synthesis of results	13	Describe the methods of handling and summarizing the	Pag 7



SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
		data that were charted.	Lines: 196-202
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	Not appropriate
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	Not appropriate
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not appropriate
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	Not appropriate
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	Not appropriate
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	Not appropriate
Limitations	20	Discuss the limitations of the scoping review process.	Pag 7 Lines: 213-235
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	Not appropriate
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	Pag 7 Lines: 250-252

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–473. doi: 10.7326/M18-0850.

